- The 8 States Most Likely to Legalize Marijuana Next
- Dow 18,000: Why This Market Rally May Never Happen Again
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
- BlackBerry Classic Review: A Bold Update for CrackBerry Fans
Why would someone as smart as Buffett buy a business perceived to be as bad as batteries?
While the company may have reported a bigger-than-expected loss, it's the broader strategy that counts.
Lots of off-balance sheet inventory will eventually have to be cleared out.
Electronic security company is trying to rely on consolidating a new acquisition to explain slumping margins.
Manufacturer of a device that treats epilepsy may be running into headwinds as other treatments for the disorder evolve.
No matter how the numbers are presented, the quality of the company's numbers leave something to be desired.
The gluten-free products maker says its results are, in effect, all part of growing pains.
A significant change in the solar panel installer's business model may signal a race to the bottom.
The multi-level marketing company is having trouble keeping its distributors.
After saying there was nothing wrong with its business model, Herbalife's strategy appears to be watering down the model in the face of increased regulatory scrutiny.